Poland
· Delayed Price · Currency is PLN Pharmena Statistics
Total Valuation
Pharmena has a market cap or net worth of PLN 51.23 million. The enterprise value is 40.59 million.
| Market Cap | 51.23M |
| Enterprise Value | 40.59M |
Important Dates
The last earnings date was Thursday, February 6, 2025.
| Earnings Date | Feb 6, 2025 |
| Ex-Dividend Date | n/a |
Share Statistics
Pharmena has 11.14 million shares outstanding.
| Current Share Class | n/a |
| Shares Outstanding | 11.14M |
| Shares Change (YoY) | n/a |
| Shares Change (QoQ) | n/a |
| Owned by Insiders (%) | 10.54% |
| Owned by Institutions (%) | 3.07% |
| Float | 3.12M |
Valuation Ratios
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | 166.35 |
| PB Ratio | 4.36 |
| P/TBV Ratio | 4.42 |
| P/FCF Ratio | n/a |
| P/OCF Ratio | n/a |
| PEG Ratio | n/a |
Enterprise Valuation
| EV / Earnings | -25.10 |
| EV / Sales | 131.77 |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | -13.62 |
Financial Position
The company has a current ratio of 16.64, with a Debt / Equity ratio of 0.01.
| Current Ratio | 16.64 |
| Quick Ratio | 15.77 |
| Debt / Equity | 0.01 |
| Debt / EBITDA | n/a |
| Debt / FCF | -0.05 |
| Interest Coverage | n/a |
Financial Efficiency
Return on equity (ROE) is -9.79% and return on invested capital (ROIC) is -12.05%.
| Return on Equity (ROE) | -9.79% |
| Return on Assets (ROA) | -10.94% |
| Return on Invested Capital (ROIC) | -12.05% |
| Return on Capital Employed (ROCE) | -28.66% |
| Revenue Per Employee | 20,533 |
| Profits Per Employee | -107,800 |
| Employee Count | 15 |
| Asset Turnover | 0.02 |
| Inventory Turnover | 0.06 |
Taxes
| Income Tax | n/a |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has decreased by -42.73% in the last 52 weeks. The beta is 0.76, so Pharmena's price volatility has been lower than the market average.
| Beta (5Y) | 0.76 |
| 52-Week Price Change | -42.73% |
| 50-Day Moving Average | 4.34 |
| 200-Day Moving Average | 5.44 |
| Relative Strength Index (RSI) | 56.35 |
| Average Volume (20 Days) | 3,890 |
Short Selling Information
| Short Interest | n/a |
| Short Previous Month | n/a |
| Short % of Shares Out | n/a |
| Short % of Float | n/a |
| Short Ratio (days to cover) | n/a |
Income Statement
In the last 12 months, Pharmena had revenue of PLN 308,000 and -1.62 million in losses. Loss per share was -0.15.
| Revenue | 308,000 |
| Gross Profit | 281,000 |
| Operating Income | -3.40M |
| Pretax Income | -2.45M |
| Net Income | -1.62M |
| EBITDA | -3.54M |
| EBIT | -3.40M |
| Loss Per Share | -0.15 |
Balance Sheet
The company has 10.80 million in cash and 155,000 in debt, giving a net cash position of 10.65 million or 0.96 per share.
| Cash & Cash Equivalents | 10.80M |
| Total Debt | 155,000 |
| Net Cash | 10.65M |
| Net Cash Per Share | 0.96 |
| Equity (Book Value) | 11.75M |
| Book Value Per Share | 1.06 |
| Working Capital | 11.27M |
Cash Flow
In the last 12 months, operating cash flow was -2.77 million and capital expenditures -208,000, giving a free cash flow of -2.98 million.
| Operating Cash Flow | -2.77M |
| Capital Expenditures | -208,000 |
| Free Cash Flow | -2.98M |
| FCF Per Share | -0.27 |
Margins
| Gross Margin | 91.23% |
| Operating Margin | -1,103.25% |
| Pretax Margin | -795.78% |
| Profit Margin | n/a |
| EBITDA Margin | n/a |
| EBIT Margin | n/a |
| FCF Margin | n/a |
Dividends & Yields
This stock pays an annual dividend of 0.85, which amounts to a dividend yield of 18.44%.
| Dividend Per Share | 0.85 |
| Dividend Yield | 18.44% |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | 2 |
| Payout Ratio | n/a |
| Buyback Yield | n/a |
| Shareholder Yield | 18.44% |
| Earnings Yield | -3.16% |
| FCF Yield | -5.82% |
Stock Splits
This stock does not have any record of stock splits.
| Last Split Date | n/a |
| Split Type | n/a |
| Split Ratio | n/a |
Scores
Pharmena has an Altman Z-Score of 53.98.
| Altman Z-Score | 53.98 |
| Piotroski F-Score | n/a |